Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide

Lucio Tentori, Carlo Leonetti, Marco Scarsella, Alessia Muzi, Matteo Vergati, Olindo Forini, Pedro Miguel Lacal, Federica Ruffini, Barry Gold, Weixing Li, Jie Zhang, Grazia Graziani

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Disruption of poly(ADP-ribose) polymerase (PARP) pathways by inhibitors of PARP catalytic domain has been shown to increase the anti-tumour activity of temozolomide (TMZ). Since PARP is inhibited by poly(ADP)ribosylation, herein we tested whether inhibition of poly(ADP-ribose) glycohydrolase (PARG) might enhance TMZ efficacy. The PARG inhibitor N-bis-(3-phenyl-propyl)9-oxo-fluorene- 2,7-diamide (GPI 16552) was administered in combination with TMZ to mice injected subcutaneously or intracranially with B16 melanoma cells. The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested. The results indicated that combined treatment with GPI 16552 and TMZ significantly reduced melanoma growth, increased life-span of mice bearing tumour at the CNS site, and decreased the ability of melanoma cells to form lung metastases and to invade the extracellular matrix. In conclusion, PARG inhibition represents an alternative strategy to enhance TMZ efficacy against melanoma in peripheral as well as at CNS site.

Original languageEnglish
Pages (from-to)2948-2957
Number of pages10
JournalEuropean Journal of Cancer
Volume41
Issue number18
DOIs
Publication statusPublished - Dec 2005

Fingerprint

temozolomide
Melanoma
Extracellular Matrix
Experimental Melanomas
Poly(ADP-ribose) Polymerases
Adenosine Diphosphate
Catalytic Domain
Neoplasms
poly ADP-ribose glycohydrolase
Neoplasm Metastasis
Lung

Keywords

  • (ADP-ribose) polymers
  • Blood-brain barrier
  • Brain tumours
  • Cancer
  • Metastasis
  • Poly(ADP-ribose) glycohydrolase
  • Poly(ADP-ribose) polymerase
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. / Tentori, Lucio; Leonetti, Carlo; Scarsella, Marco; Muzi, Alessia; Vergati, Matteo; Forini, Olindo; Lacal, Pedro Miguel; Ruffini, Federica; Gold, Barry; Li, Weixing; Zhang, Jie; Graziani, Grazia.

In: European Journal of Cancer, Vol. 41, No. 18, 12.2005, p. 2948-2957.

Research output: Contribution to journalArticle

Tentori, L, Leonetti, C, Scarsella, M, Muzi, A, Vergati, M, Forini, O, Lacal, PM, Ruffini, F, Gold, B, Li, W, Zhang, J & Graziani, G 2005, 'Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide', European Journal of Cancer, vol. 41, no. 18, pp. 2948-2957. https://doi.org/10.1016/j.ejca.2005.08.027
Tentori, Lucio ; Leonetti, Carlo ; Scarsella, Marco ; Muzi, Alessia ; Vergati, Matteo ; Forini, Olindo ; Lacal, Pedro Miguel ; Ruffini, Federica ; Gold, Barry ; Li, Weixing ; Zhang, Jie ; Graziani, Grazia. / Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. In: European Journal of Cancer. 2005 ; Vol. 41, No. 18. pp. 2948-2957.
@article{0112a355743a4eaf9c893ab877ed3575,
title = "Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide",
abstract = "Disruption of poly(ADP-ribose) polymerase (PARP) pathways by inhibitors of PARP catalytic domain has been shown to increase the anti-tumour activity of temozolomide (TMZ). Since PARP is inhibited by poly(ADP)ribosylation, herein we tested whether inhibition of poly(ADP-ribose) glycohydrolase (PARG) might enhance TMZ efficacy. The PARG inhibitor N-bis-(3-phenyl-propyl)9-oxo-fluorene- 2,7-diamide (GPI 16552) was administered in combination with TMZ to mice injected subcutaneously or intracranially with B16 melanoma cells. The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested. The results indicated that combined treatment with GPI 16552 and TMZ significantly reduced melanoma growth, increased life-span of mice bearing tumour at the CNS site, and decreased the ability of melanoma cells to form lung metastases and to invade the extracellular matrix. In conclusion, PARG inhibition represents an alternative strategy to enhance TMZ efficacy against melanoma in peripheral as well as at CNS site.",
keywords = "(ADP-ribose) polymers, Blood-brain barrier, Brain tumours, Cancer, Metastasis, Poly(ADP-ribose) glycohydrolase, Poly(ADP-ribose) polymerase, Temozolomide",
author = "Lucio Tentori and Carlo Leonetti and Marco Scarsella and Alessia Muzi and Matteo Vergati and Olindo Forini and Lacal, {Pedro Miguel} and Federica Ruffini and Barry Gold and Weixing Li and Jie Zhang and Grazia Graziani",
year = "2005",
month = "12",
doi = "10.1016/j.ejca.2005.08.027",
language = "English",
volume = "41",
pages = "2948--2957",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "18",

}

TY - JOUR

T1 - Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide

AU - Tentori, Lucio

AU - Leonetti, Carlo

AU - Scarsella, Marco

AU - Muzi, Alessia

AU - Vergati, Matteo

AU - Forini, Olindo

AU - Lacal, Pedro Miguel

AU - Ruffini, Federica

AU - Gold, Barry

AU - Li, Weixing

AU - Zhang, Jie

AU - Graziani, Grazia

PY - 2005/12

Y1 - 2005/12

N2 - Disruption of poly(ADP-ribose) polymerase (PARP) pathways by inhibitors of PARP catalytic domain has been shown to increase the anti-tumour activity of temozolomide (TMZ). Since PARP is inhibited by poly(ADP)ribosylation, herein we tested whether inhibition of poly(ADP-ribose) glycohydrolase (PARG) might enhance TMZ efficacy. The PARG inhibitor N-bis-(3-phenyl-propyl)9-oxo-fluorene- 2,7-diamide (GPI 16552) was administered in combination with TMZ to mice injected subcutaneously or intracranially with B16 melanoma cells. The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested. The results indicated that combined treatment with GPI 16552 and TMZ significantly reduced melanoma growth, increased life-span of mice bearing tumour at the CNS site, and decreased the ability of melanoma cells to form lung metastases and to invade the extracellular matrix. In conclusion, PARG inhibition represents an alternative strategy to enhance TMZ efficacy against melanoma in peripheral as well as at CNS site.

AB - Disruption of poly(ADP-ribose) polymerase (PARP) pathways by inhibitors of PARP catalytic domain has been shown to increase the anti-tumour activity of temozolomide (TMZ). Since PARP is inhibited by poly(ADP)ribosylation, herein we tested whether inhibition of poly(ADP-ribose) glycohydrolase (PARG) might enhance TMZ efficacy. The PARG inhibitor N-bis-(3-phenyl-propyl)9-oxo-fluorene- 2,7-diamide (GPI 16552) was administered in combination with TMZ to mice injected subcutaneously or intracranially with B16 melanoma cells. The ability of treatment to reduce melanoma metastatic spreading and invasion of the extracellular matrix was also tested. The results indicated that combined treatment with GPI 16552 and TMZ significantly reduced melanoma growth, increased life-span of mice bearing tumour at the CNS site, and decreased the ability of melanoma cells to form lung metastases and to invade the extracellular matrix. In conclusion, PARG inhibition represents an alternative strategy to enhance TMZ efficacy against melanoma in peripheral as well as at CNS site.

KW - (ADP-ribose) polymers

KW - Blood-brain barrier

KW - Brain tumours

KW - Cancer

KW - Metastasis

KW - Poly(ADP-ribose) glycohydrolase

KW - Poly(ADP-ribose) polymerase

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=28244465243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244465243&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.08.027

DO - 10.1016/j.ejca.2005.08.027

M3 - Article

VL - 41

SP - 2948

EP - 2957

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 18

ER -